



PRESS RELEASE

1986-2006: IBA Celebrates 20 Years At Cutting Edge Of Fight Against Cancer

Embargo until 5:40 pm (Belgian time) – April 20, 2006

Louvain-la-Neuve, Belgium, April 20, 2006 – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) celebrates its 20 years of existence in 2006. Twenty years that enabled IBA to become one of the leading players in the field of cancer diagnosis and treatment.

IBA was founded by the courage of the first shareholders, such as IRE (Institut des Radioéléments) and UCL (Université Catholique de Louvain), by financing from its first contracts guaranteed by Ducroire (OND) and grants from the Walloon region (DGTRE).

Born from an audacious bet, initially between several engineers from UCL, IBA's turnover has increased from €0.9 million to €136 million in 2005. Over 95% of sales are made abroad. Over the past twenty years, IBA has grown from a small business with 5 employees, to become an international group employing over 1,000 people worldwide, with production centers and sales offices in Europe, Asia and the United States.

Following the sale of its Sterilization & Ionization business in 2004, IBA refocused its activities on cutting edge technology for cancer treatment and diagnosis and provides best of breed products in the field.

Diagnosis

IBA has unparalleled expertise to design **cyclotrons** and produce and distribute **radiopharmaceutical markers** used in hospitals on a daily basis to accurately and promptly detect cancers, as well as heart and neurological diseases. IBA also offers **dosimetry** products used in many hospitals for quality assurance in radiodiagnostic and monitor doses administered to patients.

Therapy

IBA developed radiotherapy solutions and dosimetry equipment to treat cancer with utmost accuracy. IBA is the global leader in **proton therapy**, acknowledged as the most accurate clinical radiotherapy method, as well as the most effective for the selective destruction of cancerous cells.

The company also offers innovative responses to improve the efficacy, hygiene and safety of everyday life through **sterilization and ionization** solutions.

"Our global leadership in all fields in which we operate, results from an ongoing innovation drive, according to Pierre Mottet, CEO of IBA. Each year, IBA invests 8% of its turnover into R&D.

What we have achieved to date is therefore attributable to the unequalled dedication of our personnel for a broadly shared cause. Beyond the growth and the bottom line, it is the feeling that we are all working for a fundamental cause, to fight illnesses, and in particular, one of the worst, cancer, that prevails and incites us to go the extra mile at all times."

Corporate Identity:

"To celebrate the company's 20 years, we decided to translate our entrepreneurial and innovating spirit into a new corporate identity. The new IBA logo embodies our philosophy of using high technology for the improvement of human health and well-being. It federates IBA's various businesses, resulting from organic growth or acquisitions. On top, this logo is strongly differentiating itself from customary graphic codes of competitors."

**About IBA**

IBA delivers efficient, dependable solutions of a unique precision in the fields of cancer diagnosis and therapy. The company also offers innovative responses to improve the efficacy, hygiene and safety of everyday life through sterilization and ionization solutions. IBA is listed on the pan-European stock exchange Euronext, is integrated into the NextEconomy market segment and belongs to BelSmall index. Site: <http://www.iba-worldwide.com>

Contact**IBA**

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Tel.: +32 10 47 58 16
goethals@iba.be